3.71

0.54% +0.02

Atea Pharmaceuticals Inc (AVIR)

Overview News Price History Option Chain Discussions Forecast

Atea Pharmaceuticals Inc stock is currently priced at $3.71, with a 24-hour trading volume of 141.07K. It has seen a +0.54% increased in the last 24 hours and a -1.59% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $3.70 pivot point. If it approaches the $3.73 resistance level, significant changes may occur.

Previous Close:

$3.69

Open:

$3.71

24h Volume:

141.07K

Market Cap:

$312.25M

Revenue:

$351.37M

Net Income/Loss:

$-135.96M

P/E Ratio:

-2.8984

EPS:

-1.28

Net Cash Flow:

$-85.40M

1W Performance:

-0.27%

1M Performance:

-1.59%

6M Performance:

+21.24%

1Y Performance:

+12.08%

1D Range:

$3.6523

$3.72

52W Range:

$2.765

$5.19

Atea Pharmaceuticals Inc Stock (AVIR) Company Profile

Name

Atea Pharmaceuticals Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

857 284 8891

Address

125 Summer Street, Boston

Employee

Twitter

Next Earnings Date

2024-05-06

Latest SEC Filings

AVIR's Discussions on Twitter

Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-10-23	Downgrade	JP Morgan	Neutral → Underweight
Jan-06-22	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-18-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-20-21	Downgrade	JP Morgan	Overweight → Neutral
Oct-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-25-20	Initiated	Evercore ISI	Outperform
Nov-24-20	Initiated	JP Morgan	Overweight
Nov-24-20	Initiated	Morgan Stanley	Overweight
Nov-24-20	Initiated	William Blair	Outperform

View All

Atea Pharmaceuticals Inc Stock (AVIR) Latest News

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

GlobeNewswire Inc.

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

GlobeNewswire Inc.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire Inc.

Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study

Zacks Investment Research

Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy

Benzinga

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

GlobeNewswire Inc.

Atea Pharmaceuticals Inc Stock (AVIR) Financials Data

Atea Pharmaceuticals Inc (AVIR) Revenue 2024

AVIR reported a revenue (TTM) of $351.37 million for the quarter ending December 31, 2021.

Atea Pharmaceuticals Inc (AVIR) Net Income 2024

AVIR net income (TTM) was -$135.96 million for the quarter ending December 31, 2023, a -17.30% decrease year-over-year.

Atea Pharmaceuticals Inc (AVIR) Cash Flow 2024

AVIR recorded a free cash flow (TTM) of -$85.39 million for the quarter ending December 31, 2023, a +30.53% increase year-over-year.

Atea Pharmaceuticals Inc (AVIR) Earnings per Share 2024

AVIR earnings per share (TTM) was -$1.64 for the quarter ending December 31, 2023, a -17.14% decline year-over-year.

Atea Pharmaceuticals Inc Stock (AVIR) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Horga Maria Arantxa	Chief Medical Officer	Feb 01 '24	Sale	3.84	15,870	60,963	25,664
Corcoran Andrea	See Remarks	Feb 01 '24	Sale	3.84	15,843	60,915	670,208
Hammond Janet MJ	Chief Development Officer	Feb 01 '24	Sale	3.84	14,029	53,913	35,362
Foster Wayne	EVP, Chief Accounting Officer	Feb 01 '24	Sale	3.84	12,477	47,904	20,857
Vavricka John	Chief Commercial Officer	Feb 01 '24	Sale	3.84	11,819	45,420	21,515

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. The company's lead product candidate is AT-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2. It also develops AT-787 for the treatment of hepatitis C virus; AT-752 for the treatment of dengue; AT-889, AT-934, and other product candidates for the treatment of respiratory syncytial virus. The company was incorporated in 2012 and is based in Boston, Massachusetts.